To investigate the underlying mechanisms and biomarkers associated with IL‐17A and the role in psoriasis pathogenesis, over 30 serum proteins were evaluated in a study assessing the effectiveness and safety of secukinumab, where treatment was directly switched from cyclosporin A to secukinumab. The gene discussed is IL17A; the disease is psoriasis.